Jordan Fletcher, APRN
Primary Care · Trumann, ARNPI 1336793611
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 59 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by GSK at 29.5% of the total. Reporting peaked in 2023 at $367 and has fallen 80.3% since, to $72 in 2025.
Across 59 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$263
- Novo Nordisk$202
- AstraZeneca$82
- AbbVie$74
- Takeda Pharmaceuticals U.S.A., Inc.$59
- Otsuka America Pharmaceutical, Inc.$51
- plus $161 from 9 others
What the payments were for
- Food & beverage$891100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 19 | $263 |
| Novo Nordisk | 13 | $202 |
| AstraZeneca | 5 | $82 |
| AbbVie | 5 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $34 |
| Exact Sciences | 2 | $28 |
| Pfizer | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Amgen | 1 | $12 |
| Genentech USA, Inc. | 1 | $10 |
| Phathom Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$891 in reported general payments places this provider in the 70th percentile of 76 primary care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 76 | $901 |
| Doxycycline Hyclate | 98 | $693 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $600 |
| Ondansetron OdtOndansetron | 36 | $439 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $344 |
| Cephalexin | 45 | $229 |
| Amoxicillin | 61 | $227 |
| Azithromycin | 45 | $222 |
| Methylprednisolone | 27 | $172 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 18 | $171 |
| Clindamycin Hcl | 20 | $160 |
| Triamcinolone Acetonide | 26 | $110 |
| Fluticasone Propionate | 11 | $103 |
| Mupirocin | 14 | $101 |
| Nystatin | 11 | $97 |
Paid to pharmacies, not to this prescriber.
Other primary care in Trumann
- Andrew OliverMaumelle$45K
- Chelsea PressonLittle Rock$22K
- Stephen RohrerWynne$15K
- Chelsea MarquisSpringdale$12K
- Katherine ThompsonLittle Rock$10K
- Barbara ColeNorth Little Rock$9K
- Celeste WilliamsCenterton$6K
- Jennifer RogersCharleston$4K
- Meghan SkinnerSearcy$4K
- Krystalyn WilliamsLittle Rock$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.